Jun 04, 2019
AstraZeneca inks new deal with Starpharma
Biotech trade publication noted Starpharma signed a new development and option agreement with AstraZeneca to progress the development of a DEP® version of one of AstraZeneca's existing oncology medicines. The news builds on a previous deal between the companies related to a multiproduct licence covering novel oncology drug candidates.
Read the article here.